Shares declined 3.0% following the earnings release as investors reacted to cautious progress without clear near-term commercial milestones, reflecting concern over execution pace and an extended runway despite expense cuts.

• Established first clinical proof of concept with REC-4881 showing promising biological activity, but still early-stage with no commercial data.
• Pipeline breadth includes five wholly-owned programs with inflection points 12–18 months out, emphasizing a long timeline to potential catalysts.
• Partnered portfolio secured over $500 million in inflows with 10 milestones achieved, signaling progress but limited immediate revenue impact.
• Operating expenses reduced by 30% year-over-year, extending financial runway into early 2028, indicating ongoing capital discipline amid delayed commercialization.
• Focus remains on evolving an AI-driven drug discovery platform combining proprietary data, automation, and in-house compute, though tangible commercial value delivery remains to be demonstrated.